Claremont Creek Ventures
VC Fund
Oakland, United States
Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in companies that serve essential, broad-impact industries with innovative digital solutions that increase efficiency or create entirely new high-growth, high-margin businesses. As part of CCV’s investment strategy, the firm practices “life cycle venturing”:establishing in-depth, active relationships with entrepreneurs alongside or even ahead of early-stage funding events. Claremont Creek Ventures has invested in over 40 companies including Clean Power Finance, EcoATM, and Natera and manages more than $300 million across two funds. Visit www.claremontcreek.com.
- Total investments:
- 79
- Last investment:
- Lead investor:
- 28%
- Fund size:
- $175M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Claremont Creek Ventures invests in
Stages Claremont Creek Ventures invests in
Countries Claremont Creek Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $2M–$6.7M
- Series B
- $6M–$13M
- Series C
- $4.3M–$25M
Investment Focus
Industry
- Software 8 (10%)
- Biotechnology 8 (10%)
- Health Care 6 (8%)
- Enterprise Software 5 (6%)
- SaaS 4 (5%)
Stage
- Series A 20 (25%)
- Series B 19 (24%)
- Series C 14 (18%)
- Seed 6 (8%)
- Series D 4 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gianna Conci Orozco
Finance Manager
|
Finance Manager | Total investments: 0 | Find email | |
|
Harveen Sethi
Associate
|
Associate | Total investments: 0 | Find email | |
Nathaniel Goldhaber
Co-Founder & Managing Director
|
Co-Founder & Managing Director | Total investments: 3 | Find email | |
Randy Hawks
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
Bradford C. Webb, PhD
Venture Partner
|
Venture Partner | Total investments: 4 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Trove
|
Resale platform for Brands and Retailers. | $20M / Series C / Sep 26, 2019 | |
Trove
|
Trove is at the forefront of the branded resale and trade-in industry, providing brands with a robust platform to efficiently launch, manage, and scale their resale programs. Commanding over 75% of the U.S. branded resale market, Trove is trusted by industry leaders such as Canada Goose, Carhartt, Michael Kors, Patagonia, On, and Steve Madden.Trove’s platform features advanced tools, including in-store and digital trade-ins, returns processing, non-new inventory management, resale site building and management, Shopify integration, and peer-to-peer capabilities. These features empower brands to connect with new customers across all demographics, optimize resale strategies with comprehensive analytics, and maintain seamless operations across multiple channels.As a Certified B Corporation, Trove is more than just a technology provider; it is a catalyst for sustainability in retail, driving the industry toward a future where commerce and environmental responsibility go hand in hand. | $25M / Series C / Sep 16, 2019 | |
DNAnexus
|
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $68M / Series F / Feb 06, 2019 | |
|
DNAnexus
|
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery. It provides security, scalability, and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the worldthat are tackling some of the most challenging and exciting opportunities in human health.The company was founded in 2009 and is based in Mountain View, California. | $58M / Series E / Jan 02, 2018 | |
Blue Pillar
|
At Blue Pillar, we connect industrial equipment to the internet and serve up the data to manage, monitor, and control equipment and devices so our customers can create flexible, scalable solutions for themselves or their customers. We're energized by the challenge of making the power of Industrial IoT widely accessible. We make things alittle better in a connectivity-centric world where things are a lot harder than they should be. | $10M / Venture - Series Unknown / Jan 06, 2017 | |
Alphabet Energy
|
Alphabet Energy, Inc. is commercializing a breakthrough, inexpensive waste heat recovery technology developed at the Lawrence Berkeley National Laboratory. Our revolutionary thermoelectric approach and materials platform is the only of its kind that lends itself to massive scale at low cost. With our products, made entirely from sustainablematerials, customers may use their waste heat to generate electrical power in the range of microwatts to megawatts. | Series C / Jul 13, 2016 | |
Renew Financial
|
Renew Financial provides financing solutions that help efficiency and renewable energy contractors grow their businesses while promoting energy independence. Its aim is to develop advanced financing designed to transform America’s economy to clean energy. The company’s financing products include PACE financing model and the Warehouse for EnergyEfficiency Loans, which opens the residential energy efficiency finance market to large institutional investors.Founded in 2008 by Cisco DeVries, Renew Financial has a partnership with SolarCity targeted at small- and medium-sized businesses utilizing PACE. | $70M / Series D / Feb 11, 2016 | |
Assurerx Health
|
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $15M / Series D / Dec 21, 2015 | |
Genalyte
|
Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $44M / Series C / Aug 18, 2015 | |
NuMedii
|
NuMedii is a biotechnology company that discovers and de-risks effective new drugs by translating life sciences big data into therapies. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii. It utilizes hundreds of millions of raw human, biological,pharmacological, and clinical data points.The company was founded in 2008 and headquartered in San Mateo, California. | $2M / Series A / Aug 17, 2015 | |
| See all 79 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Claremont Creek Ventures invest in?
Claremont Creek Ventures invests primarily in Software, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 79 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Claremont Creek Ventures's check size?
Claremont Creek Ventures typically joins rounds of $2M–$6.7M at Series A, $6M–$13M at Series B and $4.3M–$25M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Claremont Creek Ventures participates in.
How do I contact Claremont Creek Ventures?
Public channels for Claremont Creek Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Claremont Creek Ventures?
The team at Claremont Creek Ventures includes Gianna Conci Orozco (Finance Manager), Harveen Sethi (Associate) and Nathaniel Goldhaber (Co-Founder & Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
